Tag: Biotechnology

axolbio
Europe

Axol Bioscience acquires Phenocell to advance human disease models

Acquisition expands Axol’s iPSC-derived cell models and service offering to include ophthalmology and dermatology CAMBRIDGE / EDINBURGH, UK, and GRASSE, FRANCE, October 2024: Axol Bioscience Ltd. (Axol), a leading induced pluripotent stem cell (iPSC) technology provider for drug discovery, today announced it has fully acquired Phenocell SAS, a pioneer in iPSC-based products and bioassays for skin and retinal disorders. The acquisition extends Axol’s portfolio of iPSC-derived cell … Continue reading Axol Bioscience acquires Phenocell to advance human disease models

Impact Newswire
Seaport Therapeutics
United States

Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round

Financing led by General Atlantic with participation from T. Rowe Price Associates, Foresite Capital, Invus, Goldman Sachs Alternatives, Canada Pension Plan Investment Board (CPP Investments) as well as other new investors Founding investors ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, and PureTech Health also participated Proceeds will support key clinical milestones in Seaport’s pipeline of first and best-in-class neuropsychiatric medicines BOSTON, October 21, 2024 … Continue reading Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round

Impact Newswire
Acticor Biotech
Europe

Acticor Biotech appoints François Guilletas Chief Financial Officer

Paris, France, Octobre 14, 2024 – 08:00am CEST – ACTICOR BIOTECH (FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today announces the appointment of François Guillet as Chief Financial Officer, replacing Éric Cohen who is leaving to pursue other projects. Gilles AVENARD, Chief Executive Officer and founder of Acticor Biotech, comments: “We are delighted to … Continue reading Acticor Biotech appoints François Guilletas Chief Financial Officer

Impact Newswire
Judo Bio
United States

Judo Bio Launches with $100 Million Financing to Develop Oligonucleotide Therapies Delivered to the Kidney and Appoints Rajiv Patni as CEO

STRIKE platform to deliver siRNA and other genetic medicines to the kidney for the treatment of systemic diseases and renal diseases Lead pipeline programs use megalin receptors for intracellular delivery of ligand-siRNA conjugates to specific kidney cells to target and silence genes, including solute carrier proteins CAMBRIDGE, Mass., October 7, 2024 — Judo Bio, a biotechnology company pioneering oligonucleotide medicines delivered to the kidney, today announced … Continue reading Judo Bio Launches with $100 Million Financing to Develop Oligonucleotide Therapies Delivered to the Kidney and Appoints Rajiv Patni as CEO

Impact Newswire
Halda Therapeutics
United States

Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer

Brings proven leadership and successful track record to Halda as the company enters the next stage of growth as clinical-stage company NEW HAVEN, Conn. – Halda Therapeutics, a biotechnology company developing a novel class of cancer therapies called RIPTAC™ (Regulated Induced Proximity TArgeting Chimeras) therapeutics, today announced that it has appointed Christian Schade as President and Chief Executive Officer and a member of the Board of … Continue reading Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer

Impact Newswire
Luxa Biotechnology
United States

Luxa Biotechnology LLC Appoints Keith E. Dionne, Ph.D., as Chief Executive Officer

FORT LEE, N.J. – Luxa Biotechnology LLC (Luxa), a clinical -stage biotechnology company developing a novel adult retinal pigment epithelial stem cell (RPESC) therapy for dry age-related macular degeneration (AMD), today announced the appointment of Keith Dionne, Ph.D. as Chief Executive Officer. “I am honored to join Luxa at such an exciting time” Post this An early pioneer in the cell therapy field and a … Continue reading Luxa Biotechnology LLC Appoints Keith E. Dionne, Ph.D., as Chief Executive Officer

Impact Newswire
VedaBio
United States

VedaBio Appoints Randy Rasmussen, Former CEO of BioFire Diagnostics, to Board of Directors

Renowned Molecular Diagnostics Leader Joins as VedaBio Enters its Next Phase of Development SAN DIEGO – VedaBio, a pioneering biotechnology company at the forefront of molecular detection, today announced the appointment of Randy Rasmussen, Ph.D., to its Board of Directors. Dr. Rasmussen, a visionary in the molecular diagnostics field with over 30 years of experience, brings deep industry knowledge to VedaBio as the company advances … Continue reading VedaBio Appoints Randy Rasmussen, Former CEO of BioFire Diagnostics, to Board of Directors

Impact Newswire
Prothena
Europe

Prothena Announces Leadership Team Updates

DUBLIN – Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Chad Swanson, Ph.D., has been appointed Chief Development Officer and will assume leadership of clinical development and medical functions. Chad will join Prothena’s executive leadership team and will report to Gene Kinney, Ph.D., President and Chief Executive Officer. Hideki … Continue reading Prothena Announces Leadership Team Updates

Impact Newswire